Cabaletta Bio (CABA) Other Accumulated Expenses (2018 - 2025)
Cabaletta Bio's quarterly Other Accumulated Expenses came in at $80000.0 in Q4 2025, up 100.0% year-on-year from $40000.0 in Q4 2024, and up 166.67% quarter-over-quarter from $30000.0 in Q3 2025.
Cabaletta Bio has reported Other Accumulated Expenses for 8 years, with the latest figure at $80000.0 in Q4 2025.
- For the quarter ending Q4 2025, Other Accumulated Expenses rose 100.0% year-over-year to $80000.0; the trailing twelve-month figure through Dec 2025 stood at $80000.0 (up 100.0% YoY), and the FY2025 full-year result was $80000.0, up 100.0% from the prior year.
- Other Accumulated Expenses for Q4 2025 stood at $80000.0, up from $30000.0 in the prior quarter.
- The five-year high for Other Accumulated Expenses was $83000.0 in Q1 2021, with the low at $16000.0 in Q2 2025.
- Average Other Accumulated Expenses over 5 years is $44150.0, with a median of $43500.0 recorded in 2021.
- Year-over-year, Other Accumulated Expenses slumped 62.86% in 2021 and jumped 100.0% in 2025.
- Tracing CABA's Other Accumulated Expenses over 5 years: stood at $54000.0 in 2021, then dropped by 27.78% to $39000.0 in 2022, then increased by 2.56% to $40000.0 in 2023, then changed by 0.0% to $40000.0 in 2024, then jumped by 100.0% to $80000.0 in 2025.
- The last three Other Accumulated Expenses figures came in at $80000.0 (Q4 2025), $30000.0 (Q3 2025), and $16000.0 (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Cabaletta Bio | 194.84 Mn | 61.24 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 80,000.00 |
| Sep 30, 2025 | 30,000.00 |
| Jun 30, 2025 | 16,000.00 |
| Mar 31, 2025 | 50,000.00 |
| Dec 31, 2024 | 40,000.00 |
| Sep 30, 2024 | 30,000.00 |
| Jun 30, 2024 | 20,000.00 |
| Mar 31, 2024 | 50,000.00 |
| Dec 31, 2023 | 40,000.00 |
| Sep 30, 2023 | 30,000.00 |
| Jun 30, 2023 | 20,000.00 |
| Mar 31, 2023 | 50,000.00 |
| Dec 31, 2022 | 39,000.00 |
| Sep 30, 2022 | 71,000.00 |
| Jun 30, 2022 | 23,000.00 |
| Mar 31, 2022 | 58,000.00 |
| Dec 31, 2021 | 54,000.00 |
| Sep 30, 2021 | 52,000.00 |
| Jun 30, 2021 | 47,000.00 |
| Mar 31, 2021 | 83,000.00 |
| Dec 31, 2020 | 38,000.00 |
| Sep 30, 2020 | 140,000.00 |
| Jun 30, 2020 | 113,000.00 |
| Mar 31, 2020 | 101,000.00 |
| Dec 31, 2019 | 177,000.00 |
| Sep 30, 2019 | 157,000.00 |
| Dec 31, 2018 | 2,000.00 |